This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.
Signed written informed consent
Age from 18 to 60 years old
Diagnosed with ITP and have a platelet count of <30 ×10^9/L on Day 1 (or within 48 hours prior to dosing on Day 1).
Patients who have no response or relapsed after splenectomy(at least more than 6 months). Or patients who have not been splenectomised and have either not responded to one or more prior therapies, or who have relapsed prior therapy.
Patients with any prior history of arterial or venous thrombosis, and with following risk factors: cancer, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome.
Pregnant or lactating women;
Subjects is currently receiving treatment with another study medication.
Any laboratory or clinical evidence for HIV infection.
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
The Second Affiliated Hospital of Kunming Medical University
Collaborator
Henan Cancer Hospital
Collaborator
Tianjin Medical University Second Hospital
Collaborator
The First Affiliated Hospital of Xiamen University
Collaborator
Affiliated Hospital of Nantong University
Collaborator